Skip to content

NEOGAP secures Eurostars funding to develop T-cell activity analysis


PRESS RELEASE. The Swedish biotech company NEOGAP Therapeutics has received SEK 5 million from Eurostars in a collaboration project with the French biotech company Okomera. The funding aims to enhance the development of an analysis method for T-cell activity against the patient’s tumour.


NEOGAP is developing pTTL, personalised Tumour Trained Lymphocytes, a tailored cell therapy that utilises modified proteins, known as neoantigens, to activate the immune system specifically against cancer cells. The therapy is currently being assessed in phase I/II clinical trials for the treatment of colorectal cancer.

As part of the Eurostars-funded project, NEOGAP collaborates with the French biotech company Okomera, which has developed an innovative method to analyse cell interactions. The method allows for the analysis of how T-cells kill tumour cells in what is known as a killing assay, requiring only a minimal quantity of the cell product. This analysis is set to deepen the understanding of the interactions between T-cells and tumour cells, potentially enabling predictions about the efficacy of NEOGAP’s cell therapy products. The goal is to develop a system that can easily and reliably measure the capability of NEOGAP’s T-cell product, pTTL, in eradicating cancer cells.

”We are very grateful for Eurostars’ backing, which not only recognises the scientific potential of our company but also reinforces our role as an innovator in analysis methods for next-generation cell therapies. The funding enables further research that is essential for advancing our cell therapy product to later clinical phases,” says Samuel Svensson, CEO of NEOGAP Therapeutics.

”Through our collaboration with NEOGAP, we’re afforded the opportunity to integrate Okomera’s technology into developing analytical methods for their pioneering cancer therapies. We eagerly anticipate the advancements this partnership will bring to the field of precision medicine,” says Sidarth Radjou, CEO of Okomera.

For more information, please contact:
Samuel Svensson, CEO
Phone: +46 733 54 21 94

About NEOGAP Therapeutics
NEOGAP Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using the patient’s own cells. The therapy is based on the company’s two technologies PIOR® and EpiTCer®. PIOR® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer® is used to multiply T cells that can recognise and attack the selected tumour-specific targets. NEOGAP is located at Cancer Center Karolinska in Stockholm. To learn more about NEOGAP and its cutting-edge research, please visit the company’s website at and follow NEOGAP on LinkedIn.

About Okomera
Okomera, a biotech startup based in Paris, develops advanced organoid screening technology for drug discovery and efficacy testing. The company’s platform features a compact bench-top device, microfluidic chips, and Hemera — an AI-powered analysis software — designed for automation to simplify organoid screening and enhance accessibility for users of all expertise levels. Okomera is evolving this technology into a versatile screening platform, initially focusing on CRISPR, T-cell potency, and drug efficacy screening. For more information, visit and follow Okomera on LinkedIn.

Access our Swedish press release on Cision’s press room
To read our press release in Swedish, please navigate to our press room on Cision, where you can access all of our latest news and announcements.